A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets

• Status: Completed
• Trial end date: 2019-12-10
• Target enrollment: 0
• Participant gender: All

Summary

A Study to Determine the Drug Level Profile of Different formulations of BMS-986165 Tablets

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: BMS-986165; Famotidine

Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Patients must be willing and able to complete all study-specific procedures and visits

• Healthy patients, as determined by no clinically significant deviation from normal in medical history, physical examination, electrocardiogram, and clinical laboratory determinations

• Body mass index (BMI) of 18 to 32 kg/m2, inclusive, at screening

• Normal renal function at screening

Exclusion Criteria:

• History or presence of chronic bacterial, viral infection, or autoimmune disorder

• Active TB requiring treatment or documented latent TB within the previous 3 years

• Current or recent (within 3 months of study treatment administration) gastrointestinal disease that could affect absorption

• WOCBP (women of childbearing potential) must have negative serum or urine pregnancy test.